ArticleClinical drug investigation2026
Change in Adherence to Oral Antidiabetic Medications Before and After Prostate Cancer Diagnosis: A Group-Based Trajectory Modeling Approach.
Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer diagnoses impact adherence to antidiabetic medications, but limited research has focused on patients with prostate cancer and type 2 diabetes (T2DM). We investigated adherence trajectories to oral antidiabetic medications one year before and after a prostate cancer diagnosis and identified risk factors.
methodsThis retrospective cohort study used the 2011-2021 MarketScan Commercial and Medicare Supplemental databases. We included newly diagnosed prostate cancer patients with T2DM with continuous insurance enrollment. We applied group-based trajectory modeling with a beta distribution to evaluate adherence patterns before and after prostate cancer diagnosis. Model covariates included age, total number of medications, number of antidiabetic medications, the Charlson Comorbidity Index (CCI), cost, insurance type, and complicated diabetes from the year before diagnosis. Metastasis and cancer treatments were included in the model after diagnosis.
resultsThe study included 7864 patients (mean age = 74.5 ± 7.1). Three adherence trajectories were identified before diagnosis: consistently high adherence, steady decliners, and consistently low adherence. After diagnosis, a fourth trajectory revealing a moderate decline emerged. Over half (61.2%) changed adherence patterns after diagnosis. Among those with consistently high adherence before diagnosis, 57.8% transitioned to a lower adherence trajectory. In contrast, 58.5% of steady decliners and 57.6% of consistently low adherents transitioned to a higher adherence trajectory after diagnosis. Predictors of high adherence included older age, fewer antidiabetic medications, lower CCI, and complicated diabetes before diagnosis. After diagnosis, fewer antidiabetic medications and complicated diabetes remained predictive of high adherence.
conclusionPatterns of adherence to oral antidiabetic medications undergo substantial changes after a prostate cancer diagnosis. Targeted interventions are needed to support and facilitate effective diabetes management in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.